Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Specific Correction of the Intron-22 Inverted Factor VIII Gene in Autologous Blood Outgrowth Endothelial Cells from Patients with Severe Hemophilia A

Long V. Dinh, PhD, Eli Fine, PhD, Afshin Ameri, MD, Bernadette W. Luu, B.S., M.T. (CLS), Satish Kumar, PhD, Vincent P. Diego, PhD, Joanne E. Curran, PhD, Juan M Peralta, M.S., Henry Mead, M.B.A., M.P.H., Miguel A. Escobar, MD, Sarah Williams-Blangero, PhD, John Blangero, PhD, Jerry S. Powell, MD, Timothy C. Nichols, MD, Robert P. Hebbel, MD, Tom E. Howard, MD, PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-142679

Published: 2020

Journal Articles

Disentangling the Effects of HLA DRB115:01 and DQB106:02 to Establish the True HLA Risk Allele for Inhibitor Development in the Treatment of Hemophilia A

Vincent P. Diego, PhD, Bernadette W. Luu, B.S., M.T. (CLS), Alexis Garza, B.S., Marco Hofmann, M.S., Marcio A. Almeida, PhD, Jerry S. Powell, MD, Long V. Dinh, PhD, Raja Rajalingam, PhD, Juan M Peralta, M.S., Satish Kumar, PhD, Eli Fine, PhD, Joanne E. Curran, PhD, Miguel A. Escobar, MD, Sarah Williams-Blangero, PhD, Eugene Maraskovsky, PhD, John Blangero, PhD, Tom E. Howard, MD, PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-142716

Published: 2020

Journal Articles

N-Linked Glycans on Therapeutic Factor VIII (FVIII) Proteins Attenuate Immunogenicity Potential: Evidence from Independent HLA-Class-II/FVIII (HLAcII/FVIII) Peptidomes

Vincent P. Diego, PhD, Bernadette W. Luu, B.S., M.T. (CLS), Hari Movva, B.S., Marco Hofmann, M.S., Marcio A. Almeida, PhD, Long V. Dinh, PhD, Jerry S. Powell, MD, Raja Rajalingam, PhD, Juan M Peralta, M.S., Henry Mead, M.B.A., M.P.H., Satish Kumar, PhD, Joanne E. Curran, PhD, Miguel A. Escobar, MD, Sarah Williams-Blangero, PhD, Eugene Maraskovsky, PhD, John Blangero, PhD, Tom E. Howard, MD, PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142493

Published: 2020

Journal Articles

The Dendritic Cell HLA-Class-II/Therapeutic Factor VIII (FVIII) Peptidome Is Influenced in Unanticipated Ways By the B-Domain of FVIII and the FVIII Chaperon Protein, Von Willebrand Factor: The Outrigger and Glycosylation-Umbrella (GUMB) Hypotheses

Tom E. Howard, MD, PhD, Bernadette W. Luu, B.S., M.T. (CLS), Marco Hofmann, M.S., Marcio A. Almeida, PhD, Satish Kumar, PhD, Long V. Dinh, PhD, Henry Mead, M.B.A., M.P.H., Jerry S. Powell, MD, Miguel A. Escobar, MD, Raja Rajalingam, PhD, Sarah Williams-Blangero, PhD, John Blangero, PhD, Maraskovsky Eugene, PhD, Vincent P. Diego, PhD

Blood (2019) 134 (Supplement_1): 161.

https://doi.org/10.1182/blood-2019-131727

Published: 2019

Journal Articles

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

Vincent P. Diego, PhD, Bernadette W. Luu, B.S., M.T. (CLS), Afshin Ameri, MD, Meera B. Chitlur, MD, Marcio A. Almeida, PhD, Karin Haack, PhD, Satish Kumar, PhD, Long V. Dinh, PhD, Henry Mead, M.B.A., M.P.H., Jerry S. Powell, MD, Miguel A. Escobar, MD, Raja Rajalingam, PhD, Sarah Williams-Blangero, PhD, Carol K. Kasper, MD, Laura Almasy, PhD, Shelley Cole, PhD, John Blangero, PhD, Tom E. Howard, MD, PhD

Blood (2019) 134 (Supplement_1): 2393.

https://doi.org/10.1182/blood-2019-132218

Published: 2019

Journal Articles

Characterization of the HLA-Class-II (HLAcII)/Therapeutic Factor VIII (FVIII)-Derived Peptidome By FVIII Domain and HLAcII Isomer

Marcio Almeida, PhD, Vincent P. Diego, PhD, Bernadette W. Luu, B.S., Marco Hofmann, M.S., Jose Antonio G. Hernandez, PhD, Juan Peralta, Joanne Curran, Miguel A Escobar, MD, Rajalingam Raja, PhD, LV Dinh, Jerry S. Powell, MD, Sarah Williams-Blangero, John Blangero, Eugene Maraskovsky, Tom Howard

Blood (2017) 130 (Supplement 1): 2352.

https://doi.org/10.1182/blood.V130.Suppl_1.2352.2352

Published: 2017

NARROW

Specific Correction of the Intron-22 Inverted Factor VIII Gene in Autologous Blood Outgrowth Endothelial Cells from Patients with Severe Hemophilia A

Disentangling the Effects of HLA DRB115:01 and DQB106:02 to Establish the True HLA Risk Allele for Inhibitor Development in the Treatment of Hemophilia A

N-Linked Glycans on Therapeutic Factor VIII (FVIII) Proteins Attenuate Immunogenicity Potential: Evidence from Independent HLA-Class-II/FVIII (HLAcII/FVIII) Peptidomes

The Dendritic Cell HLA-Class-II/Therapeutic Factor VIII (FVIII) Peptidome Is Influenced in Unanticipated Ways By the B-Domain of FVIII and the FVIII Chaperon Protein, Von Willebrand Factor: The Outrigger and Glycosylation-Umbrella (GUMB) Hypotheses

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

Characterization of the HLA-Class-II (HLAcII)/Therapeutic Factor VIII (FVIII)-Derived Peptidome By FVIII Domain and HLAcII Isomer

Email alerts

ASH Publications

American Society of Hematology

Specific Correction of the Intron-22 Inverted Factor VIII Gene in Autologous Blood Outgrowth Endothelial Cells from Patients with Severe Hemophilia A

Disentangling the Effects of HLA DRB1*15:01 and DQB1*06:02 to Establish the True HLA Risk Allele for Inhibitor Development in the Treatment of Hemophilia A

N-Linked Glycans on Therapeutic Factor VIII (FVIII) Proteins Attenuate Immunogenicity Potential: Evidence from Independent HLA-Class-II/FVIII (HLAcII/FVIII) Peptidomes

The Dendritic Cell HLA-Class-II/Therapeutic Factor VIII (FVIII) Peptidome Is Influenced in Unanticipated Ways By the B-Domain of FVIII and the FVIII Chaperon Protein, Von Willebrand Factor: The Outrigger and Glycosylation-Umbrella (GUMB) Hypotheses

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

Characterization of the HLA-Class-II (HLAcII)/Therapeutic Factor VIII (FVIII)-Derived Peptidome By FVIII Domain and HLAcII Isomer

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Disentangling the Effects of HLA DRB115:01 and DQB106:02 to Establish the True HLA Risk Allele for Inhibitor Development in the Treatment of Hemophilia A